Toronto – Eli Lilly Canada announced approval of Trulicity (dulaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults with type 2 diabetes to improve glycemic control. GLP-1 is a naturally occurring intestinal hormone that is released when people eat, causing reduced appetite and the release of insulin.1 Trulicity is delivered in a pre-filled, single-use pen with …
Indianapolis – Lilly is committed to meeting the needs of people affected by diabetes and obesity with treatment options that change the way healthcare providers can treat these diseases and offer breakthroughs for patients. The development and approvals of Mounjaro® and Zepbound® demonstrate our continued commitment to this mission. Patient safety is Lilly’s top priority, and we actively monitor, evaluate, and report …
Washington – Experts suggest people should have 1 ½ to 2 cups of fruit every day. Fruits are loaded with fibre, vital vitamins and minerals, and antioxidants that protect us against chronic illnesses like cancer, heart diseases, and mood disorders such as anxiety and depression, among others, Today reported. In terms of health, blueberries are the best fruit. The antioxidants …
Denmark – Novo Nordisk today announced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease). The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the results from an …
Innovators to help Canadian communities adopt healthy behaviours to reduce the risk of developing type 2 diabetes Ottawa – Diabetes is one of the most prevalent chronic diseases in Canada, with over 3 million people living with diabetes and 200,000 new cases diagnosed every year. Diabetes has significant impacts, loss of eyesight, nerve damage and kidney disease, on the lives …
London – Positive results from the T2NOW Phase III trial demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga (dapagliflozin) compared with patients receiving placebo.1,2 Adjusted mean change in A1C was −0.62% for Forxiga versus +0.41% for placebo, a difference of −1.03% (95% CI: -1.57-0.49; p<0.001). Statistical significance was achieved in the primary endpoint and in all …
London – A new report published in the Annals of Internal Medicine, analysed over 60,000 female nurses who stayed up late, ate unhealthy foods, exercised less, had high body mass index, slept fewer hours, smoked cigarettes, developed a risk of Type 2 diabetes. The new warning is issued to night owls by medical researchers who said they can develop diabetes …
Ottawa – Novo Nordisk spokesperson Kate Hanna in an emailed statement that they are “experiencing a temporary supply disruption with the Ozempic 1 mg (injection) pen due to the combination of overall global supply constraints coupled with increased demand.” The 0.25 mg and 0.5 mg doses of Ozempic injection pens remain available “for patients with Type 2 diabetes across Canada,” …
